PubMed Health⌕ Search

Biomedical subjects

B J Feery

Publications and source records attributed to B J Feery.

14 recordsLinked to original sources
PubMed1979

Antibody responses to influenza vaccines containing A/USSR/90/77.

Studies were undertaken in adult groups aged 17-24 years, 25-64 years and 66-100 years to determine the haemagglutination-inhibiting antibody responses to sub-unit influenza containing A/USSR/90/77 (H1N1). Antibody responses to A/USSR/90/77 were low in all groups. The young adult group (17-24 years) produced a primary response to A/USSR/90/77 and showed a significant response to a second dose of vaccine, whereas their responses to the A/Texas/1/77 (H3N2) and B/Hong Kong/8/73 components were of the anamnestic type and showed no significant increase to a second dose. The adult (25-64 years) and aged (66-100 years) groups responded anamnestically to all three vaccine components. There was no impairment of the antibody response in the aged group in comparison with the response in the adult group. A comparative assay in microtitre trays and WHO plates showed two- to four-fold differences in antibody titre to A/USSR/90/77 in these systems.

Adolescent↗
PubMed1979

Different protection rates in various groups of volunteers given subunit influenza virus vaccine in 1976.

Different rates of protection were observed in various groups of volunteers given trivalent subunit influenza virus vaccine during an epidemic caused by A/Victoria/3/75 strains of influenza virus in Melbourne, Victoria, Australia, in 1976. The degree of protection varied from 80% protection from infection in one group to a moderation in the severity of clinical illness in a geriatric group. The response to immunization may depend on the previous experience of the vaccinees, and it may be necessary to use different dose schedules in different groups for optimal protection.

Aged↗
PubMed1978

Homologous and heterologous antibody responses to subunit influenza virus vaccine.

In a group of 32 adult volunteers given subunit influenza virus vaccine containing 250 international units (i.u.) of A/Victoria/3/75, 250 i.u. of A/Scotland/840/74 and 300 i.u. of B/Hong Kong/8/73, there were substantial increases in the geometric mean homologous haemagglutination-inhibiting (HI) antibody titres. There was also substantial boosting of the antibodies to the earlier variants of the Hong Kong (H3N2) series and to a later variant of the Asian (H2N2) series. There was no boosting of antibodies to the A/FM/1/47 strain, a representative member of the H1N1 series, but two individuals showed substantial rises to A/PR/8/34 (HON1). There were increases in the HI titre of antibodies cross reactive with two recent isolations, A/Texas/1/77, and A/Victoria/35/77, but the majority of vaccinees failed to reach antibody titres likely to be protective against such strains.

Antibodies, Heterophile↗
PubMed1978

Antibody responses to influenza vaccines containing A/New Jersey/8/76.

Studies were undertaken with whole virus, subunit and adsorbed subunit influenza vaccines containing the A/New Jersey/8/76 strain to compare the antibody response induced by immunization with these vaccines. There were no significant differences in the haemagglutination-inhibiton (HI) antibody responses to A/New Jersey/8/76 induced by these vaccines in the adult groups under study. Vaccinees over 23 years of age produced good HI antibody responses to one dose of vaccine. Neuraminidase antibody and complement-fixing (CF) antibody responses were determined for the A/Victoria/3/75 component of bivalent vaccines. There were significant increases in neuraminidase inhibiting (NI) antibody titres but no increase in the complement-fixing antibody titres after vaccination.

Adolescent↗
PubMed1977

Adverse reactions after smallpox vaccination.

Nine hundred and thirty-eight reports of adverse reactions of smallpox vaccination in Australia between 1960 and 1976 have been analysed according to the type of reaction, and the age and sex of vaccinee. In an estimated 5,000,000 vaccinations, the reaction rate was 188/million, and the death rate 1-5/million. Generalized vaccinia was the most common reaction. The more serious reactions--eczema vaccinatum, progressive vaccinia, and neurological and cardiac complications--accounted for 7-4% of the reports. A small number of rarely reported non-specific inflammatory reactions is also included. There was a marked difference in the number of reactions reported in females and males (the female-male ratio was 1-6:1), and this difference increased with age. Paradoxically, of eight reports of cardiac complications, seven concerned males. The administration of vaccinial immune globulin was usually followed by a rapid resolution of the adverse reactions.

Adolescent↗
PubMed1977

Immunization with influenza vaccine in patients with haematological malignant disease.

Fifty-eight patients with a variety of haematological lymphoproliferative or myeloproliferative disorders were given bivalent subunit influenza virus vaccine, and their antibody responses after vaccination were compared with those of a normal control group. Although geometric mean titres of the patient group showed lower initial antibody levels, smaller increments, and lower final titres, after vaccination 83% of this group achieved satisfactory antibody levels to the A/Pt Chalmers strain, and 57% to the B/Hong Kong strain. The lowest antibody levels and smallest responses occurred in patients with non-Hodgkin's lymphoma, Hodgkin's disease, and multiple myeloma. Four of seven patients who showed low antibody levels, and no response to the first injection, responded to a second dose.

Adult↗
PubMed1977

Recurrent venous thrombosis with a "lupus" coagulation inhibitor in the absence of systemic lupus.

A young man presenting with recurrent deep venous thrombosis was found to have a lupus type coagulation inhibitor. He showed neither clinical nor serological evidence of systemic lupus. The value of the Russell viper venom coagulation time in the detection of the inhibitor is demonstrated. Anticoagulant therapy has not caused any bleeding complication despite the presence of the inhibitor.

Adult↗
PubMed1976

Streptococcal sore throat in general practice--a controlled study.

A controlled study was undertaken to determine the incidence of Group A haemolytic streptococci and other bacterial pathogens in throat swabs from patients presenting with sore throats. The isolation rate (38-8%) of Group A haemolytic streptococci from patients with acute tonsillitis was significantly higher than the isolation rate (8-9%) in a control group, but there was no significant difference in the isolation rates in patients diagnosed as having acute pharyngitis compared with the control group. There was no difference in the isolation rates of the other bacterial pathogens in the patient and control groups. In-vitro antibiotic studies were performed, and a comparison was made of the results of these tests and the treatment prescribed.

Acute Disease↗
PubMed1976

The specificity of nematode allergens in the diagnosis of human visceral larva migrans.

Extracts of nematodes have been used as skin test antigens in the diagnosis of nematode infections for many years. Ascaris lumbricoides and Toxocara canis are two nematodes commonly involved in human parasitism, the latter being associated with the clinical condition of Visceral Larva Migrans. In vitro and in vivo experiments reported in this paper confirm experimentally, as well as clinically, the existence of cross-reacting antigens between T. canis and Ascaris spp., and probably between T. canis and other nematodes. These cross-reactions compromise the usefulness of skin tests in the diagnosis of such parasitic infections.

Allergens↗
PubMed1976

The conquest of smallpox.

Smallpox has been a dreaded disease for thousands of years. Recurrent epidemics traversed the known world leaving a trail of death, disfigurement, and disability unparalleled by the other great plagues. Fear of smallpox provoked the first important attempts to prevent epidemic disease by a primitive form of immunization called variolation. In 1796, Edward Jenner developed the first effective vaccine against an infectious disease by using cowpox virus to prevent subsequent infection with smallpox. The discovery of this vaccine made possible the conquest of smallpox, a task that will probably be completed this year.

Adolescent↗